Mesoblast Limited (MESO, MSB.AX) said that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application or BLA for remestemcel-L for treatment of pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).
Mesoblast stated that it intends to file the resubmission during the next quarter, seeking to address all remaining product characterization issues.
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com